Sodium–glucose cotransporter 2 (SGLT2) inhibitors showed cardiorenal protection in patients with diabetes mellitus and cardiovascular disease. However, increase in lower limb amputation with canagliflozin, but not empagliflozin, was reported. The reason for this adverse effect remains speculative and whether it concerns all SGLT2 inhibitors is controversial.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
Cardiovascular Diabetology Open Access 28 April 2021
-
Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
Cardiovascular Diabetology Open Access 22 April 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Li, D. et al. Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Metab. https://doi.org/10.1016/j.diabet.2018.02.001 (2018).
Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).
Khouri, C., Cracowski, J. L. & Roustit, M. SGLT-2 inhibitors and the risk of lower-limb amputation: is this a class effect? Diabetes Obes. Metab. https://doi.org/10.1111/dom.13255 (2018).
Inzucchi, S. E. et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG OUTCOME trial. Diabetes Care 41, e4–e5 (2018).
Monami, M. et al. Toe amputations with SGLT-2 inhibitors: data from randomized clinical trials. Acta Diabetol. 54, 411–413 (2017).
Kohler, S. et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv. Ther. 34, 1707–1726 (2017).
Jabbour, S. et al. Dapagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of safety data from phase IIb/III clinical trials. Diabetes Obes. Metab. 20, 620–628 (2018).
Udell, J. A. et al. Cardiovascular outcomes and risks after initiation of a sodium glucose co-transporter 2 inhibitor: results from the EASEL population-based cohort study. Circulation https://doi.org/10.1161/CIRCULATIONAHA.117.031227 (2017).
Yuan, Z. et al. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: a retrospective cohort study. Diabetes Obes. Metab. 20, 582–589 (2018).
Fadini, G. & Avogaro, A. SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 5, 680–681 (2017).
Acknowledgements
A.J.S. has received lecturer/scientific adviser/clinical investigator fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck Sharp & Dohme, NovoNordisk, Sanofi and Servier. He worked as a clinical investigator in TECOS, LEADER, EMPA-REG OUTCOME, CANVAS-R and DECLARE trials.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Scheen, A.J. Does lower limb amputation concern all SGLT2 inhibitors?. Nat Rev Endocrinol 14, 326–328 (2018). https://doi.org/10.1038/s41574-018-0001-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41574-018-0001-9
This article is cited by
-
Therapie des Typ-2-Diabetes
Die Diabetologie (2022)
-
Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of randomized controlled trials
Cardiovascular Diabetology (2021)
-
SGLT2 inhibitors and lower limb complications: an updated meta‐analysis
Cardiovascular Diabetology (2021)
-
Therapie des Typ-2-Diabetes
Der Diabetologe (2021)
-
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
Nature Reviews Endocrinology (2020)